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Bulleted Novelty Statement 
 The NHS Diabetes Prevention Programme is performing well and expanding 
 In 2018, England became the first country in the world to achieve universal 
coverage with a Type 2 diabetes prevention programme 
 Common Type 2 diabetes is a condition of excess fat in liver and pancreas in 
susceptible people 
 The underlying processes can be reversed to normal in short duration disease, 
resulting in long term normoglycaemia  
 The mass provision of weight loss support is feasible as a vital part of our 
clinical strategy to prevent diabetes 
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Abstract 
Aim  This symposium covers the gamut of Type 2 diabetes prevention, reversing 
established Type 2 diabetes, population level delivery of weight loss programmes and 
the person insights into achieving and retaining substantial weight loss.  
Results  The NHS prevention programme was launched in 2016 with 49% 
accepting the invitation to participate and 52% of these completing the intervention. 
By March 2018, mean weight loss was 3.2kg reflecting considerable health benefits. 
Established Type 2 diabetes is now known to be a reversible condition in the early 
years, and the underlying mechanism is the removal of the excess fat from within 
liver and pancreas in these susceptible individuals. The Diabetes Remission Clinical 
Trial has shown that around half of a primary care population of people with Type 2 
diabetes of less than 6 years duration can be returned to non-diabetic blood glucose 
control which lasts at least 12 months. This raises the question of population level 
intervention to achieve weight loss. The success of some mass weight loss 
programmes requires to be recognized. Reframing mass provision of weight loss 
support should be a vital part of our clinical strategy to prevent and treat Type 2 
diabetes. However, the current obesogenic environment is a reality in which 
individuals must live. A personal account of achieving substantial and maintaining 
substantial weight loss provides invaluable insight into practical problems 
encountered. All health professionals dealing with weight control should assimilate 
and reflect upon this understanding.  
Conclusions  Effective prevention and long term reversal of Type 2 diabetes is 
feasible. The impact upon the individual must be considered during delivery of advice 
and support 
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Introduction  
This symposium deals with the critically important matter of retaining health if type 2 
diabetes threatens. Recent encouraging data from the NHS Diabetes Prevention 
Programme are discussed. The possibility of preventing onset of type 2 diabetes has 
been accepted for some time, but the potential for long-term return to normal of non-
diabetic blood glucose control is still being assimilated by health care professionals. 
The simple factor driving this common condition is now established –excess fat 
within liver and pancreas in susceptible individuals. There is a clear message for the 
wider population, which if successful, could see a fall in incidence and prevalence of 
type 2 diabetes. Prevention or reversal of established type 2 diabetes impinges upon 
real people living real lives. Even though the actions required to reverse type 2 
diabetes are straightforward, the human cost of this has to be recognized, and the 
personal account included in the symposium conveys very necessary understanding. 
 
The NHS Diabetes Prevention Programme (JV) 
The prevalence of diabetes in England has increased from 2.3 million in 2009/10 [1] 
to 3.0 million in 2015/16 [2]. Over 90% of people with diabetes have Type 2 diabetes 
[3]. The associated complication and premature mortality burden is borne by 
individuals, their families and carers [4], and by the NHS [5]. Randomised controlled 
trials in those with impaired glucose tolerance have demonstrated that onset of Type 2 
diabetes can be prevented or delayed through behavioural interventions [6; 7].  
A strategy for future healthcare in England, published in 2014, suggested a focus on 
prevention to manage demand, and proposed a national Type 2 diabetes prevention 
programme [8]. The Healthier You: NHS Diabetes Prevention Programme was 
therefore developed to prevent or delay onset of Type 2 diabetes in adults already 
identified to be at high risk, defined as having non-diabetic hyperglycaemia  (HbA1c 
42-47 mmol/mol (6.0 – 6.4%) or fasting plasma glucose 5.5-6.9 mmol/l).  Individuals 
identified following an NHS Health Check [9], through retrospective searches of 
general practice records for qualifying blood tests, or through routine clinical practice, 
are offered a place on a behavioural intervention. This approach is outlined in NICE 
Public Health Guideline PH38 [10], and will be complemented by the population-
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level interventions to tackle obesity, the major modifiable risk factor for Type 2 
diabetes, outlined in the UK Government’s Childhood Obesity Plan [11].   
Following a commissioned evidence review [12], an expert reference group 
developed a service specification for behavioural interventions and their delivery, 
which informed a national procurement for intervention providers. Four service 
providers were appointed, each with the ability to provide the behavioural 
interventions in localities across England.  The behavioural interventions enable 
weight loss, increased physical activity and improved nutrition through a minimum of 
13 face-to-face group-based sessions, over at least 9 months, constituting at least 16 
hours of contact time.  Local health economies, partnerships of Clinical 
Commissioning Groups and Local Authorities who have responsibility for 
commissioning healthcare and public health services, chose from the available 
national service providers. They undertook to identify and refer a target number of 
eligible individuals into the programme, based on local expected prevalence of those 
at risk as well as on enabling infrastructure.    
Formative evaluation has already been conducted [13], and a clinical and cost-
effectiveness evaluation of the Programme has been commissioned by the National 
Institute for Health Research that will report in 2021.   
Financial year 2016/17 constituted the first wave of national roll-out, during which 
the Programme was implemented across approximately 50% of England. Between 
June 2016 and end of March 2017, there were 43,603 referrals received, 16% higher 
than expected.  Of those referred, 49% attended the initial assessment, higher than the 
40% modelled uptake. Data on referrals, uptake, and participant characteristics were 
published [14]. As well as demonstrating referral numbers and percentage uptake in 
excess of prior modelled values, characteristics of attendees suggested that the 
programme was reaching those who are both at greater risk of developing Type 2 
diabetes and who typically access healthcare less effectively (e.g. black and minority 
ethnic groups and those resident in deprived areas). 
The second wave of national roll-out occurred during the Financial year 2017/18 
during which Programme implementation reached approximately 75% of England, 
and by the end of March 2018, 182,000 referrals had been received and 78,000 
individuals had attended an initial assessment (initial assessment precedes attendance 
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at group-based interventional sessions). There can be a delay of up to 6 months from 
referral before participants attend one of the interventional sessions, related to among 
other factors, establishing recommended group sizes and due to participant 
preferences. The interventions themselves take between 9 and 12 months to complete, 
so that by the end of March 2018, only around 4,500 participants had completed 
interventions. From this cohort, it was established that: 
1. Of those who attended at least one interventional session, 52% 
completed the intervention, where completion is defined as attendance at more 
than 60% of sessions (aligned to the Provider payment model, whereby 
Providers are paid only as participants reach each of 5 milestones, with 60% 
or more attendance at sessions at each milestone required for achievement of 
payment). 
2. Mean weight loss for completers was 3.2kg (3.1 to 3.4kg), 3.7kg if 
those of normal body-mass index at commencement were excluded. This was 
greater than had been predicted from the initial evidence review. Mean weight 
loss for all (intention-to-treat, last observation carried forward) was 2.3kg (2.2 
to 2.4kg). 
Financial year 2018/19  has constituted the final wave of national roll-out, and by 
Summer 2018, England became the first country in the world to achieve universal 
geographical coverage with a Type 2 diabetes prevention programme. By September 
2018, over 280,000 had been referred into the programme, and over 20,000 
participants had been associated with cohorts that had completed the programme. 
Data associated with this 20,000 cohort will be published shortly. 
The Department of Health and Social Care’s Mandate to NHS England for 2018-19 
[15] requires the programme to deliver 100,000 interventions per year by 2020, but 
implementation is ahead of schedule and this target will be reached in 2019. Given the 
early success of the Programme, an announcement was made on 30th November 2018 
that the Programme resources and capacity would be expanded over the next few 
years to achieve delivery of 200,000 interventions per year. 
The evidence for remote or digital delivery of interventions to prevent or delay onset 
of Type 2 diabetes is weaker than for group-based face-to-face interventions. 
However, digital modes of delivery have the potential for greater reach and lower unit 
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cost. These issues are being considered in a major uncontrolled pilot of digital 
prevention interventions conducted in live service environments as part of the 
Healthier You Programme.  
The Provider Framework is currently being re-procured, allowing opportunity to 
apply learning from the first 3 years of implementation. In contrast to the 
characteristics of initial attendees as previously described [14], retention on 
Programme has been poorer in those from black and minority ethnic groups and in 
those resident in deprived areas, and modifications to the Provider payment model 
moving forward will further incentivize retention of these specific groups. Attendance 
and retention is also poorer in those of working age, and via the re-procured Provider 
Framework, Providers will in future offer remote/digital modes of Programme 
delivery for those who decline or fail to attend the face-to-face standard offer. Further 
expansion of digital offers will be informed by the Healthier You Digital Pilot 
outlined above, due to report in early 2020. 
Data from the National Diabetes Audit in England will support Programme delivery 
evaluation from 2018/19, expanding from population-wide surveillance of those with 
diagnosed diabetes to also include those with non-diabetic hyperglycaemia. Data will 
be systematically extracted from primary care systems for those coded with any of the 
descriptors consistent with high risk of Type 2 diabetes. The extraction has been 
piloted [16] and, within data quality limits, will permit longitudinal tracking of 
individuals with non-diabetic hyperglycaemia. Linkage of this and service datasets 
from the Programme will allow evaluation of targeted prevention on type 2 diabetes 
incidence, longer-term incident microvascular and cardiovascular complications, and 
mortality. This is the first national clinical audit of those at high risk that will provide 
such longitudinal evaluation data. 
 
Those identified as being at risk of type 2 diabetes can avoid development of the 
disease, but it is likely that there will be continuing clinical presentation. Recent 
research has clarified the nature of type 2 diabetes and has led to demonstration that 
full health can be regained.  
 
Understanding type 2 diabetes and its reversibility (RT) 
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In 2006, it became possible to postulate a simple single mechanism as the cause of 
Type 2 diabetes [17]. The hypothesis was presented in a plenary lecture to Diabetes 
UK and the subsequent study, funded by Diabetes UK, was powered to test this. Was 
it possible that people with type 2 diabetes could stop medication and return to normal 
plasma glucose control during negative energy balance and if so, what were the 
underlying mechanisms? Because the effect size postulated was so large, only a small 
group size was needed to demonstrate statistical significance. The DIABETES UK 
project grant of £125,000 turned out to be good value for money.  
The resulting Counterpoint study used a very low calorie liquid formula diet, 
supplemented with non-starchy vegetables [18]. This was empirically designed to be 
acceptable for people going about their normal daily life yet able to achieve 15kg 
weight loss. The mean weight change was 15.3kg in 8 weeks, and this allowed the 
time course of return to normal fasting plasma glucose to be established. But 
importantly, the study examined the pathophysiological processes thought to be 
responsible. Within 7 days, plasma glucose had normalised due to a 30% fall in liver 
fat causing normalisation of liver insulin sensitivity. However, the most striking 
change was the reawakening of the beta cell with first phase insulin response slowly 
increasing to normal over 8 weeks.  
There was intense interest from people with diabetes about the possibility of escaping 
the disease, and because of this, the information on how-to-do-it was placed on a 
website. The subsequent emails showed that motivated individuals were able to 
achieve around 15kg weight loss at home and that this resulted in reversal of type 2 
diabetes in 73% with less than 4 years duration of type 2 diabetes, 56% with 4-8 years 
and 43% with more than 8 years duration [19]. 
Counterpoint was an acute study designed to test a hypothesis, and its results raised 
two major questions. Could the return to normal glucose metabolism be maintained 
during normal eating but avoidance of weight regain? Would people with long 
duration type 2 diabetes benefit similarly? The second study used the same dietary 
intervention, but was followed by a stepped return to normal foodstuffs, informed by 
the description by Counterpoint participants that suddenly returning to normal food 
was difficult. This was the Counterbalance study (Counteracting BetA cell failure by 
Long term Action to Normalize Calorie intake) [20]. After the re-introduction of 
normal food over 2 weeks, then monthly follow up with personal advice about food 
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quantity, normal beta cell function and normal plasma glucose control persisted for at 
least 6 months. It also showed that with increasing duration of type 2 diabetes, the 
chance of returning to the non-diabetic state gradually decreased [21]. Clearly there 
was potential for wider roll out if a suitable delivery system could be designed, 
preferably to operate in primary care, and the early results of Counterbalance 
informed the decision to conduct the Diabetes Remission Clinical Trial (DiRECT) 
with people in the first 6 years of type 2 diabetes.  
DIABETES UK played a major role in the genesis of DiRECT. Separately from the 
above studies on the pathophysiology of reversal of type 2 diabetes, Mike Lean had 
developed framework for delivery of effective weight loss in obesity per se in primary 
care. This showed that one third of obese individuals were able to sustain weight 
losses of over 15kg at one year [22]. Individual grant applications to set up a larger 
study of diabetes reversal in primary care from both RT and ML were turned down 
and Diabetes UK recommended a collaboration. An application based upon synergy 
of knowledge of how type 2 diabetes could be reversed and the training system for 
Primary Care staff was successful in being funded.  
The 12 month results of DiRECT conclusively demonstrated the feasibility of 
achieving remission of type 2 diabetes in routine Primary Care. The 8 hours of 
structured training for practice nurses (or dietitians if available) resulted in almost half 
of those recruited returning to non-diabetic control which persisted up to one year 
after the start of the intervention [23]. Given that recruitment for DiRECT was rapidly 
oversubscribed and that a remarkable 30% of all invited volunteered to participate, the 
wide applicability has been demonstrated.  
The psychological mechanisms underlying motivation and overcoming barriers have 
been identified. One particularly striking result was the very clear benefit of involving 
spouse, partner or social contacts in the decision to lose weight and during the period 
of weight loss and subsequent maintenance. The Tyneside cohort underwent detailed 
metabolic testing. This confirmed that adequate weight loss is always accompanied by 
normalisation of liver fat, hepatic fat export and pancreas fat, but even in the first 6 
years of type 2 diabetes some individuals had beta cells which had already undergone 
full dedifferentiation [24]. There was a tendency for this to be commoner in people 
with longer diabetes duration, but clearly reflected genetic factors relating to beta cell 
durability under continued metabolic stress. The bottom line of all the metabolic 
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studies can be simply stated. Type 2 diabetes is a state of excess fat inside liver and 
pancreas and removal of this allows return to non-diabetic glucose control.  
A formal economic analysis of the first 12 months of DiRECT has indicated the 
extent of value for money to taxpayers.  
Although the first year results of DiRECT are exciting, the 2nd year outcomes will 
determine for the extent of benefit to the whole population of people with type 2 
diabetes. Retention in the study has been good. The data on avoidance of weight 
regain and maintenance of remission will be separately reported.  
 
Targetted prevention programmes are essential, but if politicians and health care 
authorities could take effective action to modify the obesogenic environment, more 
widespread benefit could accrue.  
 
The success to date of population control of weight (PA) 
 
Can mass provision of weight loss support ever be a realistic strategy to prevent 
diabetes in the UK?  The evidence suggests it can and the major block to making this 
happen is the way that we, as clinicians, think about weight loss.   
 
The first block is that most overweight people and clinicians do not realise that the 
benefits of a weight loss attempt are long-lasting, even if the weight loss is temporary.  
We perceive recurrent weight loss attempts negatively- we call it yo-yo dieting- and 
in popular culture in Britain we perceive this as harmful [25].  Clinicians, who are not 
taught the science of weight loss, believe this too.[26]  However, the evidence does 
not support this common belief.  The diabetes prevention trials randomised people to 
a weight loss programme or usual care.[27; 28]  They showed initial weight loss in 
the intervention arm was followed by almost total weight regain on average, but the 
incidence of diabetes remains lower than the control group for the duration of follow-
up thus far, apparently permanently.  Weight loss also lowers blood pressure and 
improves lipid profile and there is growing evidence that temporary improvements in 
both risk factors reduces the incidence of cardiovascular disease.[29-33] 
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The second block is that we perceive overweight people as not motivated to lose 
weight because they rarely achieve weight loss [26]. However, we should instead 
view this as a failure of clinicians to engage with and offer their patients support 
because doing so makes a difference.  A trial examined patients’ responses to offering 
weight loss support in primary care to people who had a BMI of at least 30kg/m2 [34; 
35]. Eighty-three percent of those waiting to see 137 general practitioners volunteered 
and we excluded people who appeared to be motivated by dint of already acting on 
their weight, leaving 1882 participants in the trial.  GPs were trained to offer support 
in a 30-second behaviourally informed opportunistic intervention at the end of a 
routine consultation.  When GPs did so, 77% of apparently unmotivated patients 
accepted a referral to a 12-week behavioural weight loss programme and most of 
those, 40% of the total, started the programme.  Those who attended had lost 4.7kg on 
average at one year follow-up, which is similar to that achieved by apparently 
motivated people who seek out weight loss support.[36; 37]  As a result of this, 
weight loss at one year in all those offered support as part of the brief intervention 
was 2.4kg, 1.4kg greater than that achieved by the control group.  It appears that 
clinicians can easily generate motivation to lose weight and achieve weight loss in 
their patients but prefer not to do so. 
 
Thirdly, we as clinicians have a cultural block about engaging with weight loss and 
implementing the findings of this trial.[26]  But suppose we could overcome this 
block and implement the findings- what then?  We examined the impact on the 
incidence of disease, quality adjusted life years, and associated health service costs in 
relation to the costs of delivering brief interventions using the UK Health forum 
microsimulation model for the years from 2015 to 2020.  We assumed that everyone 
who visited a GP and who had a BMI of at least 30kg/m2 received a brief intervention 
and compared this scenario where no one did.  (Although the work is unpublished, it 
used a similar approach to published modelling based on the trial).[38]  The model 
predicted that it would reduce the incidence of diabetes, hypertension, and coronary 
heart disease by 11%, 11%, and 13% relative to natural trend and be cost-saving 
within a few years of implementation.  If GPs were to overcome this block, this work 
would add three hours a year to their workload, but the prize for doing so in health 
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gain, reduced workload from reduced incidence of disease, and the financial benefit to 
the nation is great. 
 
In conclusion, we need three reframings.  We need to reframe weight loss followed by 
weight regain as a partial amelioration of the problem of obesity but a permanent gain 
for health.  We can use this to spur re-engagement with a weight loss effort.  We need 
to view patients’ failure to lose weight as a reflection of our failure to offer support to 
do so.  And we need to reframe mass provision of weight loss support as a vital part 
of our clinical strategy to prevent diabetes.  The prize for doing so is great. 
 
The data from DiRECT establish the feasibility of reversal of Type 2 diabetes in 
primary care but do not adequately reflect the human dimension. Lives have to be 
lived during and after any period of weight loss. This personal account provides 
insight for all health care professional.  
 
A personal insight into reversing type 2 diabetes (David Paul) 
I've become the unlikely "poster boy" for the 800 calorie a day starvation diet to 
reverse Type 2 Diabetes in the hugely successful DiRect study. I was one of the 
original volunteers recruited and in my case it has worked spectacularly well. I shall 
remain indebted to the researchers for the rest of my life, all be it that I'm still a bit of 
a chunky chap who to the untrained eye does not appear to have ever starved in his 
life. 
I lost four stones (~25 Kg) in 12 weeks, in the first seven days of living on just four 
shakes a day my blood sugar level dropped from 13.4 to just 4.9 and more than two 
years on it's still at around that 4.9 level. I remain free of the physical and mental 
burden of being diabetic. 
But the challenge of living on four shakes a day during the actual diet is as nothing 
compared to trying to keep that weight off once you're allowed to resume eating 
normal food and get the green light to once again darken the doorway of your 
favourite pub. 
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Frankly, it's a daily battle. If you're like me, the sort of bloke who can eat and drink 
until the bathroom scales are buckling, then what's to stop you just piling the pounds 
back on again after your days on the diet start to fade in the memory? 
Well in my case it's the sheer fear of becoming diabetic once again. Having shed so 
much weight I don't want to go back to being constantly haunted by thoughts I might 
go blind from diabetes or have a foot amputated, or fearing that I'm destined to keel 
over from a stroke. 
So to that end I tried initially to control my meal portion size. Fat chance! I was given 
a hefty book packed with several hundred calorie counted meals by one of the 
diabetes nurses. I took one look, laughed at it and stuffed it in the glove compartment 
of my car. Two years on it's still in the car. Unread and unwanted and it will never 
make it into the kitchen. So the portions I served myself at meal times were too big 
and a few pounds piled on. Disaster. 
The next plan was to go on that 5-2 diet, where you eat sensibly for five days and 
hardly eat at all for the other two. If I'd been able to eat sensibly I'd never have 
become diabetic in the first place. I suspected it wouldn't work, and it didn't. And a 
few more pounds piled on. Disaster. 
So I joined my local council gym. £32 a month to sit on an exercise bike. I don't know 
which was worse, the tedium of pedalling and getting nowhere while listening to the 
lassies on the bikes beside me, debating which of the muscle bound hunks nearby that 
they liked the look of the most, or the tedium of hooking in my headphones to watch 
endless re-runs of Master Chef or Homes Under The Hammer on the computer screen 
on that dreaded exercise bike each night.  
And then I realised that having spent two hours burning off calories in the gym I'd get 
home raging with thirst and hunger and the first thing I'd do was dive into the fridge 
for a cold beer and a lump of cheese to keep me going until dinner. I'd tell myself it 
didn't matter because I must have just burned off hundreds of calories. And a few 
more pounds piled on. Disaster. 
So then sitting around the table after Christmas Dinner - and I'd just had the full 
works and was making serious inroads into the port and cheese - my family has a little 
tradition where we go public with any plans or ambitions we might have for the year 
ahead.  To everyone's surprise, including  me, and to guffaws of laughter all round, I 
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blurted out that in 2018 I would cycle from Land's End to John O'Groats, a 1,000 mile 
ride in 14 days. I had no idea whether I'd manage it, but having said it at the very least 
I'd have to try to do it and surely all the training I'd need and the actual ride itself, 
around 80 miles a day, would keep my weight down and ensure I remained diabetes 
free?  
So I went online and found a firm called Peak Tours that run what cyclists call 
"LEJOG" - shorthand for a Land's End To John O'Groats ride. And later that same 
day I delved into the garage and dug out my old bike, which hadn't seen daylight for a 
decade or more. I rode one mile down the road and a mile back. By the time I got 
home my thighs were on fire, my lungs were burning and I had to have a lie down. 
1,000 miles in a fortnight? What was I thinking? 
But then I thought about how depressed and miserable I'd been having eaten and 
drunk my way into a Type 2 Diabetes diagnosis, which until the Newcastle diet came 
along was a life sentence, and realised I'd just have to get back on the saddle. 
So I did and bit by bit I increased my regular bike rides and within a few months a 50 
mile ride was easy, soon it was 60 and 70 miles, day after day. I bought a very 
expensive new bike and even took the plunge and invested in some lycra cycling gear.  
Stepping out of the front door dressed head to toe in lycra is a big moment for a chap 
like me. It's an unforgiving fabric. I looked like a sausage on the brink of bursting. 
But you know what? Lycra actually does the job it's meant to. It makes cycling easier, 
you stay warmer and drier and can therefore cycle for longer and I decided I didn't 
care what I looked like, or what passing motorists thought, and a fair few motorists 
made me well aware of their thoughts I can assure you! Because by riding my bike 
the pounds were melting away, at last I'd discovered a way of keeping my weight 
under control while still being able to eat and drink a fair few of the things I love. 
 So I did the 1,000 mile Land's End to John O'Groats ride last September. It was quite 
a challenge not due to the cycling, because I'd done enough training> The hard bit 
was not piling on the weight because I had to stay in a different pub every night for 
two weeks with a bunch of two dozen other cyclists. Often it would be a 
Wetherspoons where the giant mixed grill at a bargain bucket £10 often proved just 
irresistible along with a fair few helpings of the £2 a pint guest ale and then the 
whisky of the week once we had all pedalled into Scotland. 
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So the net result was I cycled eight hours a day for 14 days, covered the 1,000 miles 
up hill and down dale, burning off countless calories and in that gruelling fortnight I 
lost the grand total of just seven pounds in weight. But I'd had the time of my life and 
was at least a little bit slimmer at when I got to the God foresaken town they call John 
O'Groats, being slimmer after a holiday was a first for me. 
But that was during the first year of DiRECT. The future stretches out. As a result this 
September I'll be back in the saddle again riding the length of France from Caen in 
Normandy to Nice on the Mediterranean coast - another 1,000 mile trip. The cycling 
will be just as tough as the Land's End ride, but not piling on the weight will again be 
far harder - the wine will be better and there will inevitably be a lot more cheese. But 
thanks to this research programme I'm a different person. My attitude towards food 
and how much I eat has been recalibrated and as a result my life has been totally 
transformed. 
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